349 results on '"Paul, Sudhir"'
Search Results
302. Insights into Mechanisms of Autoimmune Disease Based on Clinical Findings
- Author
-
Rose, Noel R. and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
303. The Dual Relationship Between Thymectomy and Autoimmunity : The Kaleidoscope of Autoimmune Disease
- Author
-
Sherer, Yaniv, Bar-Dayan, Yaron, Shoenfeld, Yehuda, and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
304. Mucosal Immunization for Induction of Tolerance to Autoantigens
- Author
-
Xiao, Bao-Guo, Link, Hans, and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
305. Alcohol, Anesthetics, and Analgesics in Autoimmune Reactivity
- Author
-
Thiele, Geoffrey M., Tuma, Dean J., Klassen, Lynell W., and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
306. Cell and Nuclear Penetration by Autoantibodies
- Author
-
Zack, Debra Jeske, Weisbart, Richard H., and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
307. Cellular Entry and Nuclear Localization of Anti-DNA Antibodies
- Author
-
Yanase, Kumiko, Madaio, Michael P., and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
308. DNA as Immunogen for the Induction of Immune and Autoimmune Antibody in Mice
- Author
-
Marion, Tony N. and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
309. Is the Catalytic Activity of Bence Jones Proteins an Autoimmune Effector Mechanism in Multiple Myeloma?
- Author
-
Sinohara, Hyogo, Matsuura, Kinji, and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
310. Kidney Damage in Autoimmune Disease
- Author
-
Groggel, Gerald C. and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
311. The Role of Variable Region Gene Rearrangements in the Generation of Autoantibodies
- Author
-
Davidson, Anne and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
312. Autoantibodies to T-Cell Receptors
- Author
-
Marchalonis, John J., Schluter, Samuel F., Yocum, David E., and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
313. Autoantibodies Against Ig Immunoglobulin Framework Epitopes
- Author
-
Kohler, Heinz, Müller, Sybille, and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
314. Dysregulation of the Idiotype Network in Autoimmune Diseases
- Author
-
Stafford, Haraldine A., Reichlin, Morris, and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
315. The Role of Exogenous Stimulation in Pathogenesis of Autoimmune Diseases
- Author
-
Bona, Constantin, Murai, Chihiro, Sasaki, Takeshi, and Paul, Sudhir, editor
- Published
- 1999
- Full Text
- View/download PDF
316. Specific Amyloid β Clearance by a Catalytic Antibody Construct.
- Author
-
Planque, Stephanie A., Yasuhiro Nishiyama, Sari Sonoda, Yan Lin, Hiroaki Taguchi, Mariko Hara, Kolodziej, Steven, Yukie Mitsuda, Gonzalez, Veronica, Sait, Hameetha B. R., Ken-ichiro Fukuchi, Massey, Richard J., Friedland, Robert P., O'Nuallain, Brian, Sigurdsson, Einar M., and Paul, Sudhir
- Subjects
- *
AMYLOID , *THERAPEUTIC use of immunoglobulins , *IMMUNIZATION , *HEMORRHAGE , *IMMUNITY , *PROTEIN precursors , *THERAPEUTICS - Abstract
Classical immunization methods do not generate catalytic antibodies (catabodies), but recent findings suggest that the innate antibody repertoire is a rich catabody source. We describe the specificity and amyloid β (Aβ)-clearing effect of a catabody construct engineered from innate immunity principles. The catabody recognized the AβC terminus noncovalently and hydrolyzed Aβ rapidly, with no reactivity to the Aβ precursor protein, transthyretin amyloid aggregates, or irrelevant proteins containing the catabody-sensitive Aβ dipeptide unit. The catabody dissolved preformed Aβ aggregates and inhibited Aβ aggregation more potently than an Aβ-binding IgG. Intravenous catabody treatment reduced brain Aβ deposits in amouse Alzheimer disease model without inducing microgliosis or microhemorrhages. Specific Aβ hydrolysis appears to be an innate immune function that could be applied for therapeutic Aβ removal. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
317. Metal-dependent amyloid β-degrading catalytic antibody construct.
- Author
-
Nishiyama, Yasuhiro, Taguchi, Hiroaki, Hara, Mariko, Planque, Stephanie A., Mitsuda, Yukie, and Paul, Sudhir
- Subjects
- *
AMYLOID beta-protein , *METAL catalysts , *IMMUNOGLOBULINS , *CHELATION , *HYDROLYSIS , *NUCLEOPHILIC reactions , *CONFORMATIONAL analysis - Abstract
Highlights: [•] Chelation of bound metal inhibited Aβ hydrolysis by a catalytic antibody fragment. [•] The metal accelerated a reaction step after initial antibody nucleophilic attack. [•] The hydrolytic but not chelator-inactivated antibody dissolved Aβ aggregates. [•] Zn-induced conformational transitions were associated with restored catalysis. [•] The antibody requires bound metal for efficient Aβ hydrolysis and dissolution. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
318. Physiological IgM Class Catalytic Antibodies Selective for Transthyretin Amyloid.
- Author
-
Planque, Stephanie A., Yasuhiro Nishiyama, Mariko Hara, Sonoda, Sari, Murphy, Sarah K., Kenji Watanabe, Yukie Mitsuda, Brown, Eric L., Massey, Richard J., Primmer, Stanley R., O'Nuallain, Brian, and Paul, Sudhir
- Subjects
- *
CATALYTIC antibodies , *TRANSTHYRETIN , *B cell receptors , *IMMUNOGLOBULIN M , *IMMUNOGLOBULIN G , *HYDROLYSIS , *SUPERANTIGENS - Abstract
Peptide bond-hydrolyzing catalytic antibodies (catabodies) could degrade toxic proteins, but acquired immunity principles have not provided evidence for beneficial catabodies. Transthyretin (TTR) forms misfolded β-sheet aggregates responsible for age-associated amyloidosis. We describe nucleophilic catabodies from healthy humans without amyloidosis that degraded misfolded TTR (misTTR) without reactivity to the physiological tetramericTTR(phyTTR). IgM classBcell receptors specifically recognized the electrophilic analog of misTTR but not phyTTR. IgM but not IgG class antibodies hydrolyzed the particulate and soluble misTTR species. No misTTR-IgM binding was detected. The IgMs accounted for essentially all of the misTTR hydrolytic activity of unfractionated human serum. The IgMs did not degrade non-amyloidogenic, non-superantigenic proteins. Individual monoclonal IgMs (mIgMs) expressed variable misTTR hydrolytic rates and differing oligoreactivity directed to amyloid β peptide and microbial superantigen proteins. A subset of the mIgMs was monoreactive for misTTR. Excess misTTR was dissolved by a hydrolytic mIgM. The studies reveal a novel antibody property, the innate ability of IgMs to selectively degrade and dissolve toxic misTTR species as a first line immune function. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
319. Transthyretin Aggregate-Specific Antibodies Recognize Cryptic Epitopes on Patient-Derived Amyloid Fibrils.
- Author
-
Phay, Monichan, Blinder, Veronika, Macy, Sallie, Greene, Michael J., Wooliver, Daniel C., Liu, Wen, Planas, Antoni, Walsh, Dominic M., Connors, Lawreen H., Primmer, Stanley R., Planque, Stephanie A., Paul, Sudhir, and O'Nuallain, Brian
- Subjects
- *
TRANSTHYRETIN , *EPITOPES , *AMYLOID beta-protein , *AMYLOIDOSIS diagnosis , *EXTRACELLULAR matrix proteins , *INVASIVE diagnosis - Abstract
Amyloidosis involves the extracellular deposition of proteinaceous amyloid fibrils and accessory molecules in organ(s) and/or tissue(s), and is associated with a host of human diseases, including Alzheimer disease, diabetes, and heart disease. Unfortunately, the amyloidoses are currently incurable, and there is an urgent need for less invasive diagnostics. To address this, we have generated 22 monoclonal antibodies (mAbs) against aggregates formed by a blood transport protein, transthyretin (TTR), which primarily forms amyloid fibrils in a patient's heart and/or peripheral nerves. Four of the mAbs, 2T5C9, 2G9C, T1F11, and TB2H7, demonstrated diagnostic potential in enzyme-linked immunosorbent assays (ELISA) by their low to sub-nanomolar cross-reactivity with recombinant wild-type (WT) and mutant TTR aggregates and lack of binding to native TTR or amyloid fibrils formed by other peptides or proteins. Notably, in the presence of normal human sera, three of the four mAbs, 2T5C9, 2G9C, and T1F11, retained low nM binding to TTR amyloid fibrils derived from two patients with familial amyloidotic polyneuropathy (FAP). The two most promising mAbs, 2T5C9 and 2G9C, were also shown by immunohistochemistry to have low nM binding to TTR amyloid deposits in cardiac tissue sections from two FAP patients. Taken together, these findings strongly support further investigations on the diagnostic utility of TTR aggregate specific mAbs for patients with TTR amyloidoses. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
320. Constant Domain-regulated Antibody Catalysis.
- Author
-
Sapparapu, Gopal, Planque, Stephanie, Mitsuda, Yukie, McLean, Gary, Nishiyama, Yasuhiro, and Paul, Sudhir
- Subjects
- *
CATALYSIS , *IMMUNOGLOBULIN M , *AMIDES , *PEPTIDE bonds , *PHOSPHONATES , *ANTIGENS - Abstract
Some antibodies contain variable (V) domain catalytic sites. We report the superior amide and peptide bond-hydrolyzing activity of the same heavy and light chain V domains expressed in the IgM constant domain scaffold compared with the IgG scaffold. The superior catalytic activity of recombinant IgM was evident using two substrates, a small model peptide that is hydrolyzed without involvement of high affinity epitope binding, and HIV gp120, which is recognized specifically by noncovalent means prior to the hydrolytic reaction. The catalytic activity was inhibited by an electrophilic phosphonate diester, consistent with a nucleophilic catalytic mechanism. All 13 monoclonal IgMs tested displayed robust hydrolytic activities varying over a 91-fold range, consistent with expression of the catalytic functions at distinct levels by different V domains. The catalytic activity of polyclonal IgM was superior to polyclonal IgG from the same sera, indicating that on average IgMs express the catalytic function at levels greater than IgGs. The findings indicate a favorable effect of the remote IgM constant domain scaffold on the integrity of the V-domain catalytic site and provide a structural basis for conceiving antibody catalysis as a first line immune function expressed at high levels prior to development of mature IgG class antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
321. Constitutive Production of Catalytic Antibodies to a Staphylococcus aureus Virulence Factor and Effect of Infection.
- Author
-
Brown, Eric L., Nishiyama, Yasuhiro, Dunkle, Jesse W., Aggarwal, Shreya, Planque, Stephanie, Watanabe, Kenji, Csencsits-Smith, Keri, Bowden, M. Gabriela, Kaplan, Sheldon L., and Paul, Sudhir
- Subjects
- *
SYNDECANS , *STAPHYLOCOCCUS aureus , *MICROBIAL virulence , *FIBRINOGEN , *IMMUNOGLOBULINS , *B cells - Abstract
Antibodies that recognize microbial B lymphocyte superantigenic epitopes are produced constitutively with no requirement for adaptive immune maturation. We report cleavage of the Staphylococcus aureus virulence factor extracellular fibrinogen-binding protein (Efb) by catalytic antibodies produced with no exposure to the bacterium and reduction of the catalytic antibody activity following infection. IgG catalytic antibodies that specifically hydrolyzed Efb via a nucleophilic catalytic mechanism were found in the blood of healthy humans and aseptic mice free of S. aureus infection. IgG hydrolyzed peptide bonds on the C-terminal side of basic amino acids, including a bond located within the C3b-binding domain of Efb. Efb digested with the IgG lost its ability to bind C3b and inhibit complement-dependent antibody-mediated red blood cell lysis. In addition to catalysis, the IgG expressed saturable Efb binding activity. IgG from S. aureus-infected mice displayed reduced Efb cleaving activity and increased Efb binding activity compared with uninfected controls, suggesting differing effects of the infection on the antibody subsets responsible for the two activities. IgG from children hospitalized for S. aureus infection also displayed reduced Efb cleavage compared with healthy children. These data suggest a potential defense function for constitutively produced catalytic antibodies to a putative superantigenic site of Efb, but an adaptive catalytic response appears to be proscribed. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
322. Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model.
- Author
-
Kou, Jinghong, Kim, HongDuck, Pattanayak, Abhinandan, Song, Min, Lim, Jeong-Eun, Taguchi, Hiroaki, Paul, Sudhir, Cirrito, John R., Ponnazhagan, Selvarangan, and Fukuchi, Ken-ichiro
- Subjects
- *
AMYLOID beta-protein , *ALZHEIMER'S disease , *IMMUNOTHERAPY , *CEREBRAL hemorrhage , *IMMUNOGLOBULINS - Abstract
Accumulation of amyloid-β protein (Aβ) in the brain is thought to be a causal event in Alzheimer's disease (AD). Immunotherapy targeting Aβ holds great promise for reducing Aβ in the brain. Here, we evaluated the efficacy and safety of anti-Aβ single-chain antibody (scFv59) delivery via recombinant adeno-associated virus (rAAV) on reducing Aβ deposits in an AD mouse model (TgAβPPswe/PS1dE9). First, delivery of scFv59 to the brain was optimized by injecting rAAV serotypes 1, 2, and 5 into the right lateral ventricle. Symmetrical high expression of scFv59 was found throughout the hippocampus and partly in the neocortex in both hemispheres via rAAV1 or rAAV5, while scFv59 expression via rAAV2 was mostly limited to one hemisphere. rAAV1, however, induced apoptosis and microglial activation but rAAV5 did not. Therefore, rAAV5 was selected for therapeutic scFv59 delivery in TgAβPPswe/PS1dE9 mice. rAAV5 was similarly injected into the ventricle of 10-month-old TgAβPPswe/PS1dE9 mice and 5 months later its efficacy and safety were evaluated. Immunoreactive Aβ deposits reduced in the hippocampus. Aβ42 levels in cerebrospinal fluid (CSF) tended to increase and the Aβ40 : 42 ratio decreased in CSF, suggesting that Aβ42 was relocated from the parenchyma to CSF. Hemorrhages associated with a focal increase in blood vessel amyloid were found in the brain. While immunotherapy has great potential for clearing cerebral Aβ, caution for cerebrovascular effects should be exercised when rAAV-mediated anti-Aβ immunotherapy is applied. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
323. Beneficial catalytic immunity to abeta peptide.
- Author
-
Paul S, Planque S, Nishiyama Y, Paul, Sudhir, Planque, Stephanie, and Nishiyama, Yasuhiro
- Abstract
We review attempts to treat Alzheimer disease with antibodies that bind amyloid beta peptide (Abeta) and the feasibility of developing catalytic antibodies for this purpose. Naturally occurring immunoglobulin M (IgM) class antibodies that hydrolyze Abeta and inhibit Abeta aggregation were identified. The production of these antibodies increases as a function of age, ostensibly reflecting an attempt by the immune system to protect against the deleterious effect of Abeta accumulation in old age. A search for catalytic antibodies in a library of human immunoglobulins variable (IgV) domains yielded catalysts that hydrolyzed Abeta specifically at exceptionally rapid rates. The catalytic IgVs contained the light-chain variable domains within scaffolds that are structurally reminiscent of phylogenetically ancient antibodies. Inclusion of the heavy-chain variable domain in the IgV constructs resulted in reduced catalysis. We present our view that catalytic antibodies are likely to emerge as more efficacious and safer immunotherapy reagents compared to traditional Abeta-binding antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
324. Toward Effective HIV Vaccination INDUCTION OF BINARY EPITOPE REACTIVE ANTIBODIES WITH BROAD HIV NEUTRALIZING A CTIVITY.
- Author
-
Nishiyama, Yasuhiro, Planque, Stephanie, Mitsuda, Yukie, Nitti, Giovanni, Taguchi, Hiroaki, Jin, Lei, Symersky, Jindrich, Boivin, Stephane, Sienczyk, Marcin, SaIas, Maria, Hanson, Carl V., and Paul, Sudhir
- Subjects
- *
MONOCLONAL antibodies , *AIDS vaccines , *OLIGOMERS , *EPITOPES , *PEPTIDES , *DRUG development , *CD4 antigen - Abstract
We describe murine monoclonal antibodies (mAbs) raised by immunization with an electrophilic gp120 analog (E-gp120) expressing the rare ability to neutralize genetically heterologous human immunodeficiency virus (HIV) strains. Unlike gp120, E-gp120 formed covalent oligomers. The reactivity of gp120 and E-gp120 with mAbs to reference neutralizing epitopes was markedly different, indicating their divergent structures. Epitope mapping with synthetic peptides and electrophilic peptide analogs indicated binary recognition of two distinct gp120 regions by anti-E-gp120 mAbs, the 421-433 and 288-306 peptide regions. Univalent Fab and single chain Fv fragments expressed the ability to recognize both peptides. X-ray crystallography of an anti-E-gp120 Fab fragment revealed two neighboring cavities, the typical antigen-binding cavity formed by the complementarity determining regions (CDRs) and another cavity dominated by antibody heavy chain variable (VH) domain framework (FR) residues. Substitution of the FR cavity VH Lys-19 residue by an Ala residue resulted in attenuated binding of the 421-433 region peptide probe. The CDRs and VH FR replacement/silent mutation ratios exceeded the ratio for a random mutation process, suggesting adaptive development of both putative binding sites. All mAbs studied were derived from VH1 family genes, suggesting biased recruitment of the V gene germ line repertoire by E-gp 120. The conserved 421- 433 region of gp120 is essential for HIV binding to host CD4 receptors. This region is recognized weakly by the FR of antibodies produced without exposure to HIV, but it usually fails to induce adaptive synthesis of neutralizing antibodies. We present models accounting for improved CD4-binding site recognition and broad HIV neutralizing activity of the mAbs, long sought goals in HIV vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
325. Antigen-specific Proteolysis by Hybrid Antibodies Containing Promiscuous Proteolytic Light Chains Paired with an Antigen-binding Heavy Chain.
- Author
-
Sapparapu, Gopal, Planque, Stephanie A., Nishiyama, Yasuhiro, Foung, Steven K., and Paul, Sudhir
- Subjects
- *
PROTEOLYSIS , *ANTIGENS , *IMMUNOGLOBULINS , *PROTEOLYTIC enzymes , *IMMUNE recognition , *HYDROLYSIS - Abstract
The antigen recognition site of antibodies consists of the heavy and light chain variable domains (VL and VH domains). VL domains catalyze peptide bond hydrolysis independent of VH domains (Mei, S., Mody, B., Ekiund, S. H., and Paul, S. (1991) I. Biol. Chem. 266, 15571-15574). VH domains bind antigens noncovalently independent of VL domains (Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., and Winter, G. (1989) Nature 341, 544-546). We describe specific hydrolysis of fusion proteins of the hepatitis C virus E2 protein with glutathione S-transferase (GST-E2) or FLAG peptide (FLAG-E2) by antibodies containing the VH domain of an anti-E2 IgG paired with promiscuously catalytic VL domains. The hybrid IgG hydrolyzed the E2 fusion proteins more rapidly than the unpaired light chain. An active site-directed inhibitor of serine proteases inhibited the proteolytic activity of the hybrid IgG, indicating a serine protease mechanism. The hybrid IgG displayed noncovalent E2 binding in enzyme-linked immunosorbent assay tests. Immunoblotting studies suggested hydrolysis of FLAG-E2 at a bond within E2 located ∼11 kDa from the N terminus. GST-E2 was hydrolyzed by the hybrid lgG at bonds in the GST tag. The differing cleavage pattern of FLAG-E2 and GST-E2 can be explained by the split-site model of catalysis, in which conformational differences in the E2 fusion protein substrates position alternate peptide bonds in register with the antibody catalytic subsite despite a common noncovalent binding mechanism. These studies provide proof-of-principle that the catalytic activity of a light chain can be rendered antigen-specific by pairing with a noncovalently binding heavy chain subunit. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
326. Exceptional Amyloid β Peptide Hydrolyzing Activity of Nonphysiological Immunoglobulin Variable Domain ScaffoIds.
- Author
-
Taguchi, Hiroaki, Planque, Stephanie, Sapparapu, Gopal, Boivin, Stephane, Hara, Mariko, Nishiyama, Yasuhiro, and Paul, Sudhir
- Subjects
- *
ALZHEIMER'S disease treatment , *NUCLEOPHILIC reactions , *PEPTIDES , *IMMUNOGLOBULINS , *HYDROLYSIS , *IMMUNOTHERAPY , *CLONING - Abstract
Nucleophilic sites in the paired variable domains of the light and heavy chains (V[subL] and V[subH] domains) of Ig can catalyze peptide bond hydrolysis. Amyloid β (Aβ)-binding Igs are under consideration for immunotherapy of Alzheimer disease. We searched for Aβ-hydrolyzing human IgV domains (IgVs) in a library containing a majority of single chain Fv clones mimicking physiological V[subL]-V[subH]-combining sites and minority IgV populations with nonphysiological structures generated by cloning errors. Random screening and covalent selection of phage-displayed IgVs with an electrophilic Aβ analog identified rare IgVs that hydrolyzed Aβ mainly at His[sup14]-Gln[sup15]. Inhibition of IgV catalysis and irreversible binding by an electrophilic hapten suggested a nucleophilic catalytic mechanism. Structural analysis indicated that the catalytic IgVs are nonphysiological structures, a two domain heterodimeric V[subL] (IgV[subL2]-t) and single domain V[subL] clones with aberrant polypeptide tags (IgV[subL]-t'). The IgVs hydrolyzed Aβ at rates superior to naturally occurring Igs by 3-4 orders of magnitude. Forced pairing of the single domain V[subL] with V[subH] or V[subL] domains resulted in reduced Aβ hydrolysis, suggesting catalysis by the unpaired V[subL] domain. Angstrom level amino acid displacements evident in molecular models of the two domain and unpaired V[subL] domain clones explain alterations of catalytic activity. In view of their superior catalytic activity, the V[subL] domain IgVs may help attain clearance of medically important antigens more efficiently than natural Igs. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
327. Covalent Inactivation of Factor VIII Antibodies from Hemophilia A Patients by an Electrophilic FVIII AnaIog.
- Author
-
Plariquet, Stephanie, Escobart, Miguel A., Smith, Ken C., Taguchi, Hiroaki, Nishiyama, Yasuhiro, Donnachie, Elizabeth, Pratt, Kathleen P., and Paul, Sudhir
- Subjects
- *
HEMOPHILIA , *ANTIGENS , *IMMUNOGLOBULINS , *ENZYMES , *SCISSION (Chemistry) - Abstract
The antigen-binding sites of antibodies (Abs) can express enzyme-like nucleophiles that react covalently with electrophilic compounds. We examined the irreversible and specific inactivation of antibodies (Abs) to Factor VIII (FVIII) responsible for failure of FVIII replacement therapy in hemophilia A (HA) patients. Electrophilic analogs of FVIII (E-FVIII) and its C2 domain (E-C2) were prepared by placing the strongly electrophilic phosphonate groups at surface-exposed Lys side chains of diverse antigenic epitopes. IgG Abs to FVIII from HA patients formed stable immune complexes with E-FVIII and E-C2 that were refractory to dissociation by SDS treatment and boiling, procedures that dissociate noncovalent Ab-antigen complexes. The rate-limiting step in the reaction was formation of the initial noncovalent complexes. Conversion of the initial complexes to the irreversible state occurred rapidly. The antigenic epitopes of E-FVIII were largely intact, and most of the Abs were consumed covalently. E-FVIII expressed poor FVIII cofactor activity in clotting factor assays. Nonspecific interference by E-FVIII in clotting factor function was not evident. Treatment with E-FVIII, and to a lesser extent E-C2, irreversibly relieved the FVIII inhibitory effect of HA IgG in clotting factor assays. Small FVIII peptides did not display useful reactivity, highlighting the diverse epitope specificities of the Abs and the conformational character of FVIII epitopes. E-FVIII is a prototype reagent able to attain irreversible and specific inactivation of pathogenic Abs. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
328. Towards Covalent Vaccination: IMPROVED POLYCLONAL HIV NEUTRALIZING ANTIBODY RESPONSE INDUCED BY AN ELECTROPHILIC gp 120 V3 PEPTIDE ANALOG.
- Author
-
Nishiyama, Yasuhiro, Mitsuda, Yukie, Taguchi, Hiroaki, Planque, Stephanie, Salas, Maria, Hanson, Carl V., and Paul, Sudhir
- Subjects
- *
VACCINATION , *HIV , *ANTIGENS , *IMMUNOGLOBULINS , *BACTERIA , *NUCLEOPHILIC reactions - Abstract
Rare monoclonal antibodies (Abs) can form irreversible complexes with antigens by enzyme-like covalent nucleophile-electrophile pairing. To determine the feasibility of applying irreversible antigen inactivation by Abs as the basis of vaccination against microbes, we studied the polyclonal nucleophilic Ab response induced by the electrophilic analog of a synthetic peptide corresponding to the principal neutralizing determinant (PND) of human immunodeficiency virus type-1 (HIV) gp120 located in the V3 domain. Abs from mice immunized with the PND analog containing electrophilic phosphonates (E-PND) neutralized a homologous HIV strain (MN) ∼50-fold more potently than control Abs from mice immunized with PND. The IgG fractions displayed binding to intact HIV particles. HIV complexes formed by anti-E-PND IgG dissociated noticeably more slowly than the complexes formed by anti-PND IgG. The slower dissociation kinetics are predicted to maintain long-lasting blockade of host cell receptor recognition by gp120. Pre-treatment of the anti-PND IgG with a haptenic electrophilic phosphonate compound resulted in more rapid dissociation of the HIV-IgG complexes, consistent with the hypothesis that enhanced Ab nucleophilic reactivity induced by electrophilic immunization imparts irreversible character to the complexes. These results suggest that electrophilic immunization induces a sufficiently robust nucleophilic Ab response to enhance the anti-microbial efficacy of candidate polypeptide vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
329. Antibodies to the superantigenic site of HIV-1 gp120: Hydrolytic and binding activities of the light chain subunit
- Author
-
Nishiyama, Yasuhiro, Karle, Sangeeta, Planque, Stephanie, Taguchi, Hiroaki, and Paul, Sudhir
- Subjects
- *
HIV , *LYMPHOCYTES , *GROWTH factors , *SERUM albumin - Abstract
Abstract: Antibodies (Abs) to the superantigenic determinant of HIV gp120 (gp120SAg) are potential protective agents against HIV infection. We report that the light chain subunits of Abs cloned from lupus patients using phage library methods bind and hydrolyze gp120SAg independent of the heavy chain. Unlike frequent gp120SAg recognition by intact Abs attributable to VH domain structural elements, the isolated light chains expressed this activity rarely. Four light chains capable of gp120SAg recognition were identified by fractionating phage displayed light chains using peptide probes containing gp120 residues 421–433, a gp120SAg component. Three light chains expressed non-covalent gp120SAg binding and one expressed gp120SAg hydrolyzing activity. The hydrolytic light chain was isolated by covalent phage fractionation using an electrophilic analog of residues 421–433. This light chain hydrolyzed a reporter gp120SAg substrate and full-length gp120. Other peptide substrates and proteins were hydrolyzed at lower rates or not at all. Consistent with the expected nucleophilic mechanism of hydrolysis, the light chain reacted selectively and covalently with the electrophilic gp120SAg peptide analog. The hydrolytic reaction entailed a fast initial step followed by a slower rate limiting step, suggesting rapid substrate acylation and slow deacylation. All four gp120SAg-recognizing light chains contained sequence diversifications relative to their germline gene counterparts. These observations indicate that in rare instances, the light chain subunit can bind and hydrolyze gp120SAg without the participation of the heavy chain. The pairing of such light chains with heavy chains capable of gp120SAg recognition represents a potential mechanism for generating protective Abs with enhanced HIV binding strength and anti-viral proteolytic activity. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
330. Human Monoclonal Antibody to Hepatitis C Virus E1 Glycoprotein That Blocks Virus Attachment and Viral Infectivity.
- Author
-
Zhen-Yong Keck, Sung, Vicky M. H., Perkins, Susan, Rowe, Judy, Paul, Sudhir, Liang, T. Jake, Lai, Michael M. C., and Foung, Steven K. H.
- Subjects
- *
MONOCLONAL antibodies , *GLYCOPROTEINS , *HEPATITIS C virus , *VACCINES , *VIRUS diseases , *VIROLOGY - Abstract
Human antibodies elicited in response to hepatitis C virus (HCV) infection are anticipated to react with the native conformation of the viral envelope structure. Isolation of these antibodies as human monoclonal antibodies that block virus binding and entry will be useful in providing potential therapeutic reagents and for vaccine development. H-111, an antibody to HCV envelope 1 protein (El) that maps to the YEVRNVSGVYH sequence and is located near the N terminus of E1 and is able to immunoprecipitate E1E2 heterodimers, is described. Binding of H-111 to HCV E1 genotypes 1a, 1b, 2b, and 3a indicates that the H-111 epitope is highly conserved. Sequence analysis of antibody V regions showed evidence of somatic and affinity maturation of H-111. Finally, H-111 blocks HCV-like particle binding to and HCV virion infection of target cells, suggesting the involvement of this epitope in virus binding and entry. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
331. Catalytic antibody (catabody) platform for age-associated amyloid disease: From Heisenberg's uncertainty principle to the verge of medical interventions.
- Author
-
Planque SA, Massey RJ, and Paul S
- Subjects
- Alzheimer Vaccines pharmacology, Amyloid beta-Peptides metabolism, Humans, Immunogenicity, Vaccine, Protein Folding, Aging physiology, Amyloidosis immunology, Amyloidosis metabolism, Amyloidosis prevention & control, Antibodies, Catalytic physiology, Homeostasis physiology
- Abstract
Quantum mechanics-based design of useful catalytic antibodies (catabodies) failed because of the uncertain structure of the dynamic catalyst-substrate complex. The Catabody Platform emerged from discovery of beneficial germline gene catabodies that hydrolyzed self-proteins by transient covalent pairing of the strong catabody nucleophile with a weak target protein electrophile. Catabodies have evolved by Darwinian natural selection for protection against misfolded self-proteins that threatened survival by causing amyloid disease. Ancient antibody scaffolds upregulate the catalytic activity of the antibody variable (V) domains. Healthy humans universally produce beneficial catabodies specific for at least 3 misfolded self-proteins, transthyretin, amyloid β peptide and tau protein. Catabody are superior to ordinary antibodies because of catalyst reuse for thousands of target destruction cycles with little or no risk of causing inflammation, a must for non-toxic removal of abundant targets such as amyloids. Library mining with electrophilic target analogs (ETAs) isolates therapy-grade catabodies (fast, specific). Ex vivo- and in vivo-verified catabodies specific for the misfolded protein are available to dissolve brain, cardiac and vertebral amyloids. Immunization with ETAs overcomes important ordinary vaccine limitations (no catabody induction, poor immunogenicity of key target epitopes). We conceive electrophilic longevity vaccines that can induce catabody synthesis for long-lasting protection against amyloid disease., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
332. Significance tests for analyzing gene expression data with small sample sizes.
- Author
-
Ullah I, Paul S, Hong Z, and Wang YG
- Subjects
- Biometry, Monte Carlo Method, Sample Size, Statistical Distributions, Gene Expression
- Abstract
Motivation: Under two biologically different conditions, we are often interested in identifying differentially expressed genes. It is usually the case that the assumption of equal variances on the two groups is violated for many genes where a large number of them are required to be filtered or ranked. In these cases, exact tests are unavailable and the Welch's approximate test is most reliable one. The Welch's test involves two layers of approximations: approximating the distribution of the statistic by a t-distribution, which in turn depends on approximate degrees of freedom. This study attempts to improve upon Welch's approximate test by avoiding one layer of approximation., Results: We introduce a new distribution that generalizes the t-distribution and propose a Monte Carlo based test that uses only one layer of approximation for statistical inferences. Experimental results based on extensive simulation studies show that the Monte Carol based tests enhance the statistical power and performs better than Welch's t-approximation, especially when the equal variance assumption is not met and the sample size of the sample with a larger variance is smaller. We analyzed two gene-expression datasets, namely the childhood acute lymphoblastic leukemia gene-expression dataset with 22 283 genes and Golden Spike dataset produced by a controlled experiment with 13 966 genes. The new test identified additional genes of interest in both datasets. Some of these genes have been proven to play important roles in medical literature., Availability and Implementation: R scripts and the R package mcBFtest is available in CRAN and to reproduce all reported results are available at the GitHub repository, https://github.com/iullah1980/MCTcodes., Supplementary Information: Supplementary data is available at Bioinformatics online., (© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
333. Estimation for zero-inflated beta-binomial regression model with missing response data.
- Author
-
Luo R and Paul S
- Subjects
- Algorithms, Likelihood Functions, Poisson Distribution, Toxicology statistics & numerical data, Bias, Models, Statistical, Regression Analysis
- Abstract
Discrete data in the form of proportions with overdispersion and zero inflation can arise in toxicology and other similar fields. In regression analysis of such data, another problem that also may arise in practice is that some responses may be missing. In this paper, we develop estimation procedure for the parameters of a zero-inflated overdispersed binomial model in the presence of missing responses under three different missing data mechanisms. A weighted expectation maximization algorithm is used for the maximum likelihood estimation of the parameters involved. Extensive simulations are conducted to study the properties of the estimates in terms of average of estimates, relative bias, variance, mean squared error, and coverage probability of estimates. Simulations show much superior properties of the estimates obtained using the weighted expectation maximization algorithm. Some illustrative examples and a discussion are given., (Copyright © 2018 John Wiley & Sons, Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
334. Hydrolysis and Dissolution of Amyloids by Catabodies.
- Author
-
Meretoja VV, Paul S, and Planque SA
- Subjects
- Amyloid beta-Peptides chemistry, Antibodies, Catalytic isolation & purification, Humans, Hydrolysis, Immunoglobulin M immunology, Immunoglobulin M isolation & purification, Immunoglobulin M metabolism, Solubility, Substrate Specificity, Amyloid beta-Peptides immunology, Amyloid beta-Peptides metabolism, Antibodies, Catalytic immunology, Antibodies, Catalytic metabolism
- Abstract
Catalytic antibodies (catabodies) hold potential for superior immunotherapy because of their turnover capability and no or minimal induction of inflammatory responses. Catabodies neutralize and remove target antigens more potently than conventional antibodies. Depending on the catalytic rate constant, a single catabody molecule degrades thousands to millions of target molecules over its useful lifespan, whereas conventional antibodies only form reversibly associated, stoichiometric complexes with the target. Thus, removal of the antibody-bound target requires accessory phagocytic cells that ingest the immune complexes, which is usually accompanied by release of inflammatory mediators. In comparison, catabodies bind the target only transiently, and the rapid and direct target destruction reduces the concentration of immune complexes that can activate inflammatory processes. These features are especially pertinent when large target amounts at anatomically vulnerable sites must be removed, e.g., amyloids. We reported specific catabodies to misfolded transthyretin (misTTR) amyloid and amyloid β peptide (Aβ). Accumulation of the oligomeric and fibrillized amyloid TTR forms causes diverse systemic pathologies, including cardiomyopathy, polyneuropathy, and skeletal diseases. Brain Aβ aggregates are thought to cause central nervous system degenerative disease, chiefly Alzheimer's disease. We describe methods for testing catabody-mediated degradation and dissolution of Aβ and TTR.
- Published
- 2017
- Full Text
- View/download PDF
335. Erratum to: Hydrolysis and Dissolution of Amyloids by Catabodies.
- Author
-
Meretoja VV, Paul S, and Planque SA
- Published
- 2017
- Full Text
- View/download PDF
336. Estimation for zero-inflated over-dispersed count data model with missing response.
- Author
-
Mian R and Paul S
- Subjects
- Algorithms, Humans, Models, Statistical, Likelihood Functions, Poisson Distribution
- Abstract
In this paper, we develop estimation procedure for the parameters of a zero-inflated over-dispersed/under-dispersed count model in the presence of missing responses. In particular, we deal with a zero-inflated extended negative binomial model in the presence of missing responses. A weighted expectation maximization algorithm is used for the maximum likelihood estimation of the parameters involved. Some simulations are conducted to study the properties of the estimators. Robustness of the procedure is shown when count data follow other over-dispersed models, such as the log-normal mixture of the Poisson distribution or even from a zero-inflated Poisson model. An illustrative example and a discussion leading to some conclusions are given. Copyright © 2016 John Wiley & Sons, Ltd., (Copyright © 2016 John Wiley & Sons, Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
337. Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications.
- Author
-
Kou J, Yang J, Lim JE, Pattanayak A, Song M, Planque S, Paul S, and Fukuchi K
- Subjects
- Alzheimer Disease cerebrospinal fluid, Alzheimer Disease complications, Amyloid beta-Peptides metabolism, Animals, Antibodies pharmacology, Cerebral Amyloid Angiopathy etiology, Cerebral Amyloid Angiopathy pathology, Cerebral Hemorrhage etiology, Cerebral Hemorrhage pathology, Dependovirus metabolism, Disease Models, Animal, Genetic Vectors metabolism, HEK293 Cells, Hippocampus drug effects, Hippocampus metabolism, Humans, Inflammation pathology, Injections, Mice, Inbred C57BL, Microglia drug effects, Microglia metabolism, Microglia pathology, Monocytes drug effects, Monocytes metabolism, Monocytes pathology, Neocortex drug effects, Neocortex metabolism, Neocortex pathology, Plaque, Amyloid metabolism, Solubility, Alzheimer Disease prevention & control, Alzheimer Disease therapy, Biocatalysis drug effects, Genes, Immunoglobulin, Genetic Therapy
- Abstract
Accumulation of amyloid beta-peptide (Aβ) in the brain is hypothesized to be a causal event leading to dementia in Alzheimer's disease (AD). Aβ vaccination removes Aβ deposits from the brain. Aβ immunotherapy, however, may cause T cell- and/or Fc-receptor-mediated brain inflammation and relocate parenchymal Aβ deposits to blood vessels leading to cerebral hemorrhages. Because catalytic antibodies do not form stable immune complexes and Aβ fragments produced by catalytic antibodies are less likely to form aggregates, Aβ-specific catalytic antibodies may have safer therapeutic profiles than reversibly-binding anti-Aβ antibodies. Additionally, catalytic antibodies may remove Aβ more efficiently than binding antibodies because a single catalytic antibody can hydrolyze thousands of Aβ molecules. We previously isolated Aβ-specific catalytic antibody, IgVL5D3, with strong Aβ-hydrolyzing activity. Here, we evaluated the prophylactic and therapeutic efficacy of brain-targeted IgVL5D3 gene delivery via recombinant adeno-associated virus serotype 9 (rAAV9) in an AD mouse model. One single injection of rAAV9-IgVL5D3 into the right ventricle of AD model mice yielded widespread, high expression of IgVL5D3 in the unilateral hemisphere. IgVL5D3 expression was readily detectable in the contralateral hemisphere but to a much lesser extent. IgVL5D3 expression was also confirmed in the cerebrospinal fluid. Prophylactic and therapeutic injection of rAAV9-IgVL5D3 reduced Aβ load in the ipsilateral hippocampus of AD model mice. No evidence of hemorrhages, increased vascular amyloid deposits, increased proinflammatory cytokines, or infiltrating T-cells in the brains was found in the experimental animals. AAV9-mediated anti-Aβ catalytic antibody brain delivery can be prophylactic and therapeutic options for AD.
- Published
- 2015
- Full Text
- View/download PDF
338. Small sample GEE estimation of regression parameters for longitudinal data.
- Author
-
Paul S and Zhang X
- Subjects
- Bias, Cluster Analysis, Humans, Probability, Sample Size, Longitudinal Studies, Models, Statistical
- Abstract
Longitudinal (clustered) response data arise in many bio-statistical applications which, in general, cannot be assumed to be independent. Generalized estimating equation (GEE) is a widely used method to estimate marginal regression parameters for correlated responses. The advantage of the GEE is that the estimates of the regression parameters are asymptotically unbiased even if the correlation structure is misspecified, although their small sample properties are not known. In this paper, two bias adjusted GEE estimators of the regression parameters in longitudinal data are obtained when the number of subjects is small. One is based on a bias correction, and the other is based on a bias reduction. Simulations show that the performances of both the bias-corrected methods are similar in terms of bias, efficiency, coverage probability, average coverage length, impact of misspecification of correlation structure, and impact of cluster size on bias correction. Both these methods show superior properties over the GEE estimates for small samples. Further, analysis of data involving a small number of subjects also shows improvement in bias, MSE, standard error, and length of the confidence interval of the estimates by the two bias adjusted methods over the GEE estimates. For small to moderate sample sizes (N ≤50), either of the bias-corrected methods GEEBc and GEEBr can be used. However, the method GEEBc should be preferred over GEEBr, as the former is computationally easier. For large sample sizes, the GEE method can be used., (Copyright © 2014 John Wiley & Sons, Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
339. Modified Gaussian estimation for correlated binary data.
- Author
-
Zhang X and Paul S
- Subjects
- Air Pollution adverse effects, Biometry, Child, Cities statistics & numerical data, Humans, Longitudinal Studies, Normal Distribution, Public Health statistics & numerical data, Regression Analysis, Models, Statistical
- Abstract
In this paper, we develop a Gaussian estimation (GE) procedure to estimate the parameters of a regression model for correlated (longitudinal) binary response data using a working correlation matrix. A two-step iterative procedure is proposed for estimating the regression parameters by the GE method and the correlation parameters by the method of moments. Consistency properties of the estimators are discussed. A simulation study was conducted to compare 11 estimators of the regression parameters, namely, four versions of the GE, five versions of the generalized estimating equations (GEEs), and two versions of the weighted GEE. Simulations show that (i) the Gaussian estimates have the smallest mean square error and best coverage probability if the working correlation structure is correctly specified and (ii) when the working correlation structure is correctly specified, the GE and the GEE with exchangeable correlation structure perform best as opposed to when the correlation structure is misspecified., (© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2013
- Full Text
- View/download PDF
340. Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.
- Author
-
Yang J, Pattanayak A, Song M, Kou J, Taguchi H, Paul S, Ponnazhagan S, Lalonde R, and Fukuchi K
- Subjects
- Alzheimer Disease metabolism, Amyloid beta-Peptides blood, Amyloid beta-Peptides cerebrospinal fluid, Amyloid beta-Peptides immunology, Animals, Dependovirus genetics, Disease Models, Animal, Gene Expression, Gene Targeting, Genetic Therapy, Immunization, Passive, Mice, Mice, Inbred C57BL, Muscles metabolism, Single-Chain Antibodies metabolism, Alzheimer Disease therapy, Amyloid beta-Peptides metabolism, Brain metabolism, Single-Chain Antibodies genetics
- Abstract
We previously reported that anti-amyloid-beta (Aβ) single-chain antibody (scFv59) brain delivery via recombinant adeno-associated virus (rAAV) was effective in reducing cerebral Aβ load in an Alzheimer's disease (AD) mouse model without inducing inflammation. Here, we investigated the prophylactic effects and mechanism of a muscle-directed gene therapy modality in an AD mouse model. We injected rAAV serotype 1 encoding scFv59 into the right thigh muscles of 3-month-old mice. Nine months later, high levels of scFv59 expression were confirmed in the thigh muscles by both immunoblotting and immunohistochemistry. As controls, model mice were similarly injected with rAAV1 encoding antihuman immunodeficiency virus Gag antibody (scFvGag). AAV1-mediated scFv59 gene delivery was effective in decreasing Aβ deposits in the brain. Compared with the scFvGag group, levels of Aβ in cerebrospinal fluid (CSF) decreased significantly while Aβ in serum tended to increase in the scFv59 group. AAV1-mediated scFv59 gene delivery may alter the equilibrium of Aβ between the blood and brain, resulting in an increased efflux of Aβ from the brain owing to antibody-mediated sequestration/clearance of peripheral Aβ. Our results suggest that muscle-directed scFv59 delivery via rAAV1 may be a prophylactic option for AD and that levels of CSF Aβ may be used to evaluate the efficacy of anti-Aβ immunotherapy.
- Published
- 2013
- Full Text
- View/download PDF
341. CD4 binding determinant mimicry for HIV vaccine design.
- Author
-
Nishiyama Y, Planque S, Hanson CV, Massey RJ, and Paul S
- Abstract
The immunodominant epitopes expressed by the HIV-1 envelope protein gp120 are hypermutable, defeating attempts to develop an effective HIV vaccine. Targeting the structurally conserved gp120 determinant that binds host CD4 receptors (CD4BD) and initiates infection is a more promising route to vaccination, but this has proved difficult because of the conformational flexibility of gp120 and immune evasion mechanisms used by the virus. Mimicking the outer CD4BD conformational epitopes is difficult because of their discontinuous nature. The CD4BD region composed of residues 421-433 (CD4BD(core)) is a linear epitope, but this region possesses B cell superantigenic character. While superantigen epitopes are vulnerable to a small subset of spontaneously produced neutralizing antibodies present in humans without infection (innate antibodies), their non-covalent binding to B cell receptors (BCRs) does not stimulate an effective adaptive response from B cells. Covalent binding at naturally occurring nucleophilic sites of the BCRs by an electrophilic gp120 (E-gp120) analog is a promising solution. E-gp120 induces the synthesis of neutralizing antibodies the CD4BD(core). The highly energetic covalent reaction is hypothesized to convert the abortive superantigens-BCR interaction into a stimulatory signal, and the binding of a spatially distinct epitope at the traditional combining site of the BCRs may furnish a second stimulatory signal. Flexible synthetic peptides can detect pre-existing CD4BD(core)-specific neutralizing antibodies. However, induced-fit conformational transitions of the peptides dictated by the antibody combining site structure may induce the synthesis of non-neutralizing antibodies. Successful vaccine targeting of the CD4BD will require a sufficiently rigid immunogen that mimics the native epitope conformation and bypasses B cell checkpoints restricting synthesis of the neutralizing antibodies.
- Published
- 2012
- Full Text
- View/download PDF
342. Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.
- Author
-
Planque SA, Mitsuda Y, Nishiyama Y, Karle S, Boivin S, Salas M, Morris MK, Hara M, Liao G, Massey RJ, Hanson CV, and Paul S
- Subjects
- Amino Acid Sequence, Animals, Antibodies, Neutralizing biosynthesis, CD4 Antigens immunology, CD4 Antigens metabolism, Epitopes immunology, Epitopes metabolism, HIV Antibodies biosynthesis, HIV Envelope Protein gp120 chemistry, HIV Infections immunology, HIV Infections prevention & control, HIV-1 chemistry, Humans, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic immunology, Mice, Molecular Sequence Data, Neutralization Tests, Recombinant Proteins biosynthesis, Recombinant Proteins immunology, Single-Chain Antibodies biosynthesis, Single-Chain Antibodies immunology, Superantigens chemistry, AIDS Vaccines biosynthesis, Antibodies, Neutralizing immunology, HIV Antibodies immunology, HIV Envelope Protein gp120 immunology, HIV-1 immunology, Superantigens immunology
- Abstract
Failure to induce synthesis of neutralizing Abs to the CD4 binding determinant (CD4BD) of gp120, a central objective in HIV vaccine research, has been alternately ascribed to insufficient immunogen binding to Abs in their germline V region configuration expressed as BCRs, insufficient adaptive mutations in Ab V regions, and conformational instability of gp120. We employed peptide analogs of gp120 residues 421-433 within the CD4BD (CD4BD(core)) to identify Abs produced without prior exposure to HIV (constitutive Abs). The CD4BD(core) peptide was recognized by single-chain Fv fragments from noninfected humans with lupus that neutralized genetically diverse strains belonging to various HIV subtypes. Replacing the framework region (FR) of a V(H)4-family single-chain Fv with the corresponding V(H)3-family FRs from single-chain Fv JL427 improved the CD4BD(core) peptide-binding activity, suggesting a CD4BD(core) binding site outside the pocket formed by the CDRs. Replacement mutations in the FR site vicinity suggested the potential for adaptive improvement. A very small subset of serum CD4BD(core)-specific serum IgAs from noninfected humans without autoimmune disease isolated by epitope-specific chromatography neutralized the virus potently. A CD4BD(core)-specific, HIV neutralizing murine IgM with H and L chain V regions (V(H) and V(L) regions) free of immunogen-driven somatic mutations was induced by immunization with a CD4BD(core) peptide analog containing an electrophilic group that binds B cells covalently. The studies indicate broad and potent HIV neutralization by constitutive Abs as an innate, germline-encoded activity directed to the superantigenic CD4BD(core) epitope that is available for amplification for vaccination against HIV.
- Published
- 2012
- Full Text
- View/download PDF
343. Nature and nurture of catalytic antibodies.
- Author
-
Paul S, Planque SA, Nishiyama Y, Hanson CV, and Massey RJ
- Subjects
- Animals, B-Lymphocytes immunology, Communicable Diseases immunology, Complementarity Determining Regions chemistry, Complementarity Determining Regions immunology, Humans, Immunoglobulin A chemistry, Immunoglobulin G chemistry, Immunoglobulin M chemistry, Immunoglobulin Variable Region chemistry, Immunoglobulin Variable Region immunology, Receptors, Antigen, B-Cell immunology, Superantigens immunology, Antibodies, Catalytic immunology, Autoantibodies immunology, Immunoglobulin A immunology, Immunoglobulin G immunology, Immunoglobulin M immunology
- Abstract
Immunoglobulins (antibodies) frequently express constitutive functions. Two such functions are nucleophilic catalysis and the reversible binding to B-cell superantigens. Constitutive or "naturally-occurring" antibodies are produced spontaneously from germline genetic information. The antibody structural elements mediating the constitutive functions have originated over millions of years of phylogenic evolution, contrasting with antigen-driven, somatic sequence diversification of the complementarity determining regions (CDR) that underlies the better-known high affinity antigen binding function of antibodies. Often, the framework regions (FRs) play a dominant role in antibody constitutive functions. Catalytic antibody subsets with promiscuous, autoantigen-directed and microbe-directed specificities have been identified. Mucosal antibodies may be specialized to express high-level catalytic activity against microbes transmitted by the mucosal route, exemplified by constitutive production of IgA class antibodies in mucosal secretions that catalyze the cleavage of HIV gp120. Catalytic specificity can be gained by constitutive noncovalent superantigen binding at the FRs and by adaptive development of noncovalent classical antigen or superantigen binding, respectively, at the CDRs and FRs. Growing evidence suggests important functional roles for catalytic antibodies in homeostasis, autoimmune disease and protection against infection. Adaptive antibody responses to microbial superantigens are proscribed underphysiological circumstances. Covalent electrophilic immunogen binding to constitutively expressed nucleophilic sites in B-cell receptors bypasses the restriction on adaptive antibody production, and simultaneous occupancy of the CDR binding site by a stimulatory antigenic epitope can also overcome the downregulatory effect of superantigen binding at the FRs. These concepts may be useful for developing novel vaccines that capitalize and improve on constitutive antibody functions for protection against microbes.
- Published
- 2012
- Full Text
- View/download PDF
344. Back to the future: covalent epitope-based HIV vaccine development.
- Author
-
Paul S, Planque S, Nishiyama Y, Escobar M, and Hanson C
- Subjects
- Antibodies, Neutralizing blood, Biomedical Research trends, Epitopes chemistry, HIV Antibodies blood, HIV Envelope Protein gp120 chemistry, Humans, Models, Molecular, Protein Structure, Tertiary, Superantigens immunology, env Gene Products, Human Immunodeficiency Virus immunology, AIDS Vaccines immunology, Epitopes immunology, HIV Envelope Protein gp120 immunology, HIV Infections prevention & control
- Abstract
Traditional HIV vaccine approaches have proved ineffective because the immunodominant viral epitopes are mutable and the conserved epitopes necessary for infection are not sufficiently immunogenic. The CD4 binding site expressed by the HIV envelope protein of glycoprotein 120 is essential for viral entry into host cells. In this article, we review the B-cell superantigenic character of the CD4 binding site as the cause of its poor immunogenicity. We summarize evidence supporting development of covalent immunization as the first vaccine strategy with the potential to induce an antibody response to a conserved HIV epitope that neutralizes genetically divergent HIV strains.
- Published
- 2010
- Full Text
- View/download PDF
345. Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.
- Author
-
Paul S, Planque S, and Nishiyama Y
- Subjects
- Alzheimer Disease immunology, Alzheimer Disease therapy, Humans, Hydrolysis, Immunity, Innate, Immunoglobulin G immunology, Immunoglobulin M immunology, Immunoglobulins, Intravenous immunology, Immunoglobulins, Intravenous therapeutic use, Models, Immunological, Peptide Fragments analysis, Amyloid beta-Peptides immunology, Antibodies, Catalytic immunology, Autoantibodies immunology, Autoantigens immunology
- Abstract
Objectives: Objectives The objectives of this study are to (1) evaluate the ability of the immune system to synthesize specific antibodies that catalyze the degradation of amyloid beta peptide (Abeta) and to (2) evaluate the prospect of developing a catalytic IVIG (CIVIG) formulation for therapy of Alzheimer's disease (AD)., Conclusions: Polyclonal autoantibodies from humans without dementia hydrolyzed Abeta specifically. The catalytic activity improved as a function of age. Patients with AD produced catalytic antibodies at increased levels. IgM-class antibodies expressed the activity at levels superior to IgGs. Production of catalytic autoantibodies appears to be an innate immunity function with adaptive improvements occurring upon Abeta overexpression, which suggests a beneficial function of the catalytic activity. The catalytic autoantibodies impeded Abeta aggregation, dissolved preformed Abeta aggregates, and inhibited Abeta cytotoxicity in tissue culture. Recombinant catalytic antibodies from a human library have been identified, validating the phenomenon of antibody-catalyzed Abeta cleavage. As a single catalyst molecule inactivates multiple Abeta molecules, catalytic antibodies may clear Abeta efficiently. IVIG did not cleave Abeta, indicating the importance of purification procedures that maintain catalytic site integrity. Traditional Abeta-binding antibodies form immune complexes that can induce inflammatory reaction and vascular dysfunction. Catalysts do not form stable immune complexes, minimizing these risks. Criteria appropriate for developing a CIVIG formulation with potential therapeutic utility are discussed, including isolation of the Abeta-specific catalytic subsets present in IgM and IgG from human blood.
- Published
- 2010
- Full Text
- View/download PDF
346. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection.
- Author
-
Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, Morris MK, Nishiyama Y, Ghosh D, Kumar A, Gao F, Hanson CV, and Paul S
- Subjects
- Binding Sites, CD4 Antigens genetics, Enzyme-Linked Immunosorbent Assay, Epitopes, HIV Envelope Protein gp120 genetics, HIV Infections genetics, HIV Infections virology, Humans, Neutralization Tests, Survivors, AIDS Vaccines immunology, CD4 Antigens immunology, HIV Envelope Protein gp120 immunology, HIV Infections immunology, HIV-1 immunology
- Abstract
Objective: To identify an HIV epitope suitable for vaccine development., Design: Diverse HIV-1 strains express few structurally constant regions on their surface vulnerable to neutralizing antibodies. The mostly conserved CD4-binding site (CD4BS) of gp120 is essential for host cell binding and infection by the virus. Antibodies that recognize the CD4BS are rare, and one component of the CD4BS, the 421-433 peptide region, expresses B-cell superantigenic character, a property predicted to impair the anti-CD4BS adaptive immune response., Methods: IgA samples purified from the plasma of patients with HIV infection were analyzed for the ability to bind synthetic mimetics containing the 416-433 gp120 region and full-length gp120. Infection of peripheral blood mononuclear cells by clinical HIV isolates was measured by p24 ELISA., Results: IgA preparations from three patients with subtype B infection for 19-21 years neutralized heterologous, coreceptor CCR5-dependent subtype A, B, C, D, and AE strains with exceptional potency. The IgAs displayed specific binding of a synthetic 416-433 peptide mimetic dependent on recognition of the CD4-binding residues located in this region. Immunoadsorption, affinity chromatography, and mutation procedures indicated that HIV neutralization occurred by IgA recognition of the CD4BS., Conclusion: These observations identify the 421-433 peptide region as a vulnerable HIV site to which survivors of infection can produce powerful neutralizing antibodies. This indicates that the human immune system can bypass restrictions on the adaptive B cell response to the CD4BS, opening the route to targeting the 421-433 region for attaining control of HIV infection.
- Published
- 2010
- Full Text
- View/download PDF
347. A covalent HIV vaccine: is there hope for the future?
- Author
-
Paul S, Planque SA, Nishiyama Y, and Hanson CV
- Published
- 2009
- Full Text
- View/download PDF
348. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library.
- Author
-
Karle S, Planque S, Nishiyama Y, Taguchi H, Zhou YX, Salas M, Lake D, Thiagarajan P, Arnett F, Hanson CV, and Paul S
- Subjects
- Dose-Response Relationship, Immunologic, Humans, Leukocytes, Mononuclear immunology, Epitopes immunology, HIV Envelope Protein gp120 metabolism, HIV Infections immunology, HIV-1 immunology, Immunoglobulin Fragments immunology
- Abstract
A single-chain fragment containing antibody V domains (scFv) isolated from a lupus antibody library displayed the ability to bind gp120 and the conserved gp120 determinant composed of residues 421-436. The scFv neutralized R5 and X4-dependent HIV-1 strains from clades B, C, and D. The lupus repertoire may be useful as a source of neutralizing antibodies to HIV.
- Published
- 2004
- Full Text
- View/download PDF
349. Degradation of beta-amyloid by proteolytic antibody light chains.
- Author
-
Rangan SK, Liu R, Brune D, Planque S, Paul S, and Sierks MR
- Subjects
- Alzheimer Disease metabolism, Amyloid Precursor Protein Secretases, Amyloid beta-Peptides immunology, Animals, Antibodies, Monoclonal metabolism, Aspartic Acid Endopeptidases, Carboxypeptidases immunology, Carboxypeptidases metabolism, Catalysis, Chromogenic Compounds metabolism, Endopeptidases immunology, Humans, Hydrolysis, Immunoglobulin Fragments metabolism, Kinetics, Lysine metabolism, Mass Spectrometry, Mice, Peptide Fragments immunology, Substrate Specificity, Amyloid beta-Peptides metabolism, Endopeptidases metabolism, Immunoglobulin Light Chains metabolism, Lysine analogs & derivatives, Peptide Fragments metabolism
- Abstract
Deposition of beta-amyloid (Abeta) is considered an important early event in the pathogenesis of Alzheimer's disease (AD). Clearance of Abeta thus represents a potential therapeutic approach. Antibody-mediated clearance of Abeta by vaccination inhibited and cleared Abeta deposition in animal models; however, inflammatory side effects were observed in humans. An alternative potentially noninflammatory approach to facilitate clearance is to proteolytically cleave Abeta. We screened 12 proteolytic recombinant antibody fragments for potential alpha-secretase activity, a naturally occurring enzyme that cleaves between the Lys16 and Leu17 residues of the amyloid precursor protein (APP). We utilized the synthetic alpha-secretase substrate, benzyloxycarbonyl-l-lysine o-nitrophenyl ester (Z-lys-o-Np) as a preliminary screen for alpha-secretase activity. Two antibody light chain fragments that hydrolyzed Z-lys-o-Np were identified. Abeta hydrolysis was studied using mass spectrometry to identify the cleavage patterns of the antibodies. The recombinant antibody light chain antibody fragment, c23.5, showed alpha-secretase-like activity, producing the 1-16 and 17-40 amino acid fragments of Abeta. The second light chain antibody fragment, hk14, demonstrated carboxypeptidase-like activity, cleaving sequentially from the carboxyl terminal of Abeta. These antibody light chains provide a novel route toward engineering efficient therapeutic antibodies capable of cleaving Abeta in vivo.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.